丙型肝炎病毒相关冷球蛋白血症性血管炎患者病毒学治愈后的长期结局
该前瞻性研究纳入46例丙型肝炎病毒相关冷球蛋白血症性血管炎(HCV-CV)患者和42例无症状冷球蛋白血症患者,评估直接抗病毒药物(DAA)清除病毒后的长期临床与免疫效果。DAA治疗后中位24个月,66%的HCV-CV患者和70%的无症状患者出现免疫学应答,冷球蛋白比容从2.6%降至0%(P < .05);但20%患者冷球蛋白检测仍阳性。91%的HCV-CV患者获得临床应答,伯明翰血管炎活动度评分(第3版)从7降至0(P < .01);然而持续病毒学应答后2年内,11%的HCV-CV患者血管炎复发,包括严重器官损害和死亡。
要点
- DAA治疗后中位24个月,66%的HCV-CV患者和70%的无症状冷球蛋白血症患者出现免疫学应答,冷球蛋白比容从2.6%降至0%(P < .05)。
- 20%的患者在DAA治疗后冷球蛋白检测仍为阳性。
- 91%的HCV-CV患者获得临床应答,伯明翰血管炎活动度评分(第3版)从7降至0(P < .01);但11%的患者在持续病毒学应答后2年内血管炎复发,包括严重器官损害和死亡。
核心结论
- DAA治疗可使多数HCV-CV患者获得临床和免疫学应答,但部分患者冷球蛋白持续阳性,且持续病毒学应答后2年内仍可出现血管炎复发,包括严重器官损害和死亡。
研究设计与样本
- 前瞻性研究,纳入46例HCV-CV患者和42例无症状冷球蛋白血症患者,评估DAA清除HCV后的长期临床与免疫效果,中位随访24个月(范围17-41个月)。
主要发现
- DAA治疗后中位24个月,66%的HCV-CV患者和70%的无症状冷球蛋白血症患者出现免疫学应答,冷球蛋白比容从2.6%降至0%(P < .05)。
- 20%的患者在DAA治疗后冷球蛋白检测仍为阳性。
- 46例HCV-CV患者中42例(91%)获得临床应答,伯明翰血管炎活动度评分(第3版)从7降至0(P < .01)。
- 持续病毒学应答后2年内,5例HCV-CV患者(11%,其中4例有肝硬化)血管炎复发,包括严重器官损害和死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with hepatitis C virus-associated cryoglobulinemic vasculitis (HCV-CV) have high rates of clinical remission after treatment with direct-acting antivirals (DAAs), but circulating cryoglobulins persist, and vascular disorders reappear in some patients shortly after DAA treatment ends. We performed a prospective study to assess the long-term clinical and immune system effects of HCV eradication with DAAs in 46 patients with HCV-CV and 42 asymptomatic patients with circulating cryoglobulins. A median of 24 months after DAA treatment (range, 17-41 months), 66% of patients with HCV-CV and 70% of asymptomatic patients with circulating cryoglobulins had an immunologic response, with comparable reductions in cryocrit from 2.6% to 0% (P < .05). However, 20% of patients still had positive test results for cryoglobulins after DAA therapy. Among patients with HCV-CV, 42 (91%) had a clinical response, in that their Birmingham Vasculitis Activity Score (version 3) decreased from 7 to 0 (P < .01). Nevertheless, within 2 years after a sustained viral response to DAA therapy, 5 patients with HCV-CV (11%, 4 with cirrhosis) had relapses of vasculitis that included severe organ damage and death.
引用
- Bonacci M, Lens S, Mariño Z, et al. Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. Gastroenterology. 2018. PMID: 29705529. doi:10.1053/j.gastro.2018.04.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。